La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
COMPASS Pathways Croissance future
Future contrôle des critères 0/6
COMPASS Pathways devrait augmenter ses bénéfices et son chiffre d'affaires de 40.3% et de 76.7% par an respectivement. Le BPA devrait croître de de 41.4% par an. Le rendement des capitaux propres devrait être -146.5% dans 3 ans.
Informations clés
40.3%
Taux de croissance des bénéfices
41.4%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.3% |
Taux de croissance des recettes | 76.7% |
Rendement futur des capitaux propres | -146.5% |
Couverture par les analystes | Good |
Dernière mise à jour | 15 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18COMPASS Pathways: Risky But Can Pay Back Generously
Dec 14Compass Pathways: An Overvalued Psychedelic Company With A Single Mediocre Drug
Nov 23COMPASS Pathways ADS reports Q3 results
Nov 12Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 28 | -195 | -176 | -166 | 6 |
12/31/2025 | N/A | -173 | -134 | -129 | 7 |
12/31/2024 | N/A | -156 | -116 | -113 | 8 |
6/30/2024 | N/A | -139 | -100 | -100 | N/A |
3/31/2024 | N/A | -129 | -91 | -90 | N/A |
12/31/2023 | N/A | -118 | -97 | -97 | N/A |
9/30/2023 | N/A | -117 | -115 | -115 | N/A |
6/30/2023 | N/A | -102 | -117 | -117 | N/A |
3/31/2023 | N/A | -95 | -111 | -110 | N/A |
12/31/2022 | N/A | -92 | -106 | -105 | N/A |
9/30/2022 | N/A | -86 | -83 | -83 | N/A |
6/30/2022 | N/A | -84 | -78 | -77 | N/A |
3/31/2022 | N/A | -80 | -77 | -77 | N/A |
12/31/2021 | N/A | -72 | -68 | -68 | N/A |
9/30/2021 | N/A | -65 | -62 | -62 | N/A |
6/30/2021 | N/A | -66 | -62 | -62 | N/A |
3/31/2021 | N/A | -64 | -51 | -51 | N/A |
12/31/2020 | N/A | -60 | -42 | -41 | N/A |
9/30/2020 | N/A | -49 | -31 | -31 | N/A |
6/30/2020 | N/A | -38 | -22 | -22 | N/A |
3/31/2020 | N/A | -25 | -19 | -19 | N/A |
12/31/2019 | N/A | -20 | -18 | -18 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: CMPS devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: CMPS devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: CMPS devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: CMPS ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: CMPS ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: CMPS devrait être non rentable dans 3 ans.